Click here to narrow your options by answering a few questions.
   

Prostate Cancer Treatment Guide

Treatment
Description
Prostate Cancer
Patient Profile
Prostate Cancer
Treatments
Prostate Cancer
Survival Rates
Prostate Cancer
Side Effects
Therapy News View Procedures Share Your Experience

Chemotherapy

Prostate Chemotherapy

Chemotherapy may be used in advanced prostate cancer, if the disease has extended to other parts of the body. Prostate Chemotherapy

Chemotherapy may be used in advanced prostate cancer, if the disease has extended to other parts of the body.

click to learn more

Learn More

Recurrent Prostate Cancer

Recurrent prostate cancer that has stopped responding to treatment may benefit from chemotherapy. Recurrent
Prostate Cancer

Recurrent prostate cancer that has stopped responding to treatment may benefit from chemotherapy.

click to learn more

Learn More

Salvage Chemotherapy

Chemotherapy is administered orally, or by a computerized pump, or by frequent injections at a doctor’s office. Salvage Chemotherapy

Chemotherapy is administered orally, or by a computerized pump, or by frequent injections at a doctor’s office.

click to learn more

Learn More

Effects
of Chemotherapy

Chemotherapy may relieve pain and slow tumor growth in advanced stages of prostate cancer. Effects
of Chemotherapy

Chemotherapy may relieve pain and slow tumor growth in advanced stages of prostate cancer.

click to learn more

 

Chemotherapy
Side Effects

Chemotherapy may cause nausea, hair loss, vomiting, and mouth sores. Chemotherapy Side Effects

Chemotherapy may cause nausea, hair loss, vomiting, and mouth sores.

click to learn more

Learn More

Prostate News

Click here for the latest news on chemotherapy.Prostate News

Click here for the latest news on chemotherapy.

click to learn more

Learn More

Chemotherapy
Videos

Click here to view chemotherapy procedures. Chemotherapy
Videos

Click here to view chemotherapy procedures.

click to learn more

Learn More

Chemotherapy
Experience


Click here to share your chemotherapy experiences.Chemotherapy
Experience

Click here to share your chemotherapy experiences.

click to learn more


Learn More

Brachytherapy

Cryosurgery &
Cryotherapy

Hormone
Therapy

Radiation
Therapy

Prostatectomy

Robotic Prostatectomy

Watchful
Waiting

Complementary
and
Alternative Medicine

High Intensity
Focused
Ultrasound (HIFU)

Emerging Technologies

 

Results of Treating Prostate Cancer
with Chemotherapy

“First Evidence That Chemotherapy Extends Life in Advanced Prostate Cancer”
Daniel Petrylak, M.D. of Columbia University, et al.

Conducted by numerous cooperative groups, this study evaluated 770 men with advanced prostate cancer that were no longer responding to hormone therapy. At random the patients were given chemotherapy regimens with the drugs docetaxel and estramustine or with prednisone and mitoxantrone. After approximately 32 months physicians followed -up with their participants. Those patients who received docetaxel and estramustine lived for about 18 months and those who were treated with prednisone and mitoxantrone lived for about 16 months. In patients treated with docetaxel and estramustine the progression of their cancer was delayed for twice as long. Also their prostate specific antigen level decreased more in patients treated with docetaxel and estramustine. However, patients that underwent docetaxel and estramustine chemotherapy did report more frequent severe side effects including stomach and heart problems.


“Combination of Cancer Drugs Increases Survival Rate of Some Prostate Cancer Patients: New Research Shows”
Derek Raghavan, M.D. (director of the Cleveland Clinic Taussig Cancer Center, and one of the leaders of the Genitourinary Committee of the Southwest Oncology Group), et al.

This study evaluated 770 men with advanced, hormone refractory prostate cancer. Of the participants, 386 received a combination of docetaxel and estramustine, and 384 received mitoxantrone and prednisone. The results showed that those who were treated with docetaxel and estramustine had a longer survival rate of 17.5 months compared with 15.6 months for patients treated with mitoxantrone and prednisone. Those who received docetaxel and estramustine experienced a 50% decline in their PSA level compared with a 27% decline for patients who received mitoxantrone and prednisone. Patients in both groups reported similar pain relief following treatment. Those given docetaxel and estramustine experienced moderate levels of fever, gastrointestinal, and cardiac side effects more frequently than those who were treated with mitoxantrone and prednisone.


“Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer”
Mario Eisenberger M.D. (R. Dale Hughes Professor of Oncology at Johns Hopkins Kimmel Cancer Center) Dr. Ian Tannock of Princess Margaret Hospital (senior scientist with Ontario Cancer Institute and professor with the University of Toronto), et al.

With the involvement of this study involved 24 countries tracked more than 1,006 patients with advanced prostate cancer who failed to respond well to hormone therapy. At random patients were divided into three groups: one group received the standard chemotherapy with mitoxantrone, and the other two groups received docetaxel either every three weeks or weekly. All three groups received low daily doses of prednisone. After comparing all three groups it was shown that men who received docetaxel administered every three weeks saw an improved survival rate by an average of 3 months. However those who received docetaxel weekly and those receiving mitoxantrone had no significant difference in their survival rate.


“Study Shows Benefits of Adding High-Dose Vitamin D to Chemotherapy for Advanced Prostate Cancer: Presented at ASCO”
Tomasz Beer M.D., an oncologist at the Oregon Health and Science University Cancer Institute in Portland Oregon, et al.

This study evaluated 37 men with hormone-refractory prostate cancer. Patients in the study received oral calcitriol (or active vitamin D), on the first day of the treatment cycle, followed by an infusion of docetaxel on the following day. This treatment was repeated weekly for six weeks. The results of this trial found that the docetaxel/calcitriol combination was twice as effective as docetaxel alone. The study revealed that 81% of patients treated with the combination regimen reduced their PSA levels by more than half. In addition to PSA response, eight out of 15 men with measurable prostate cancer experienced reductions in their tumors.

 
 
 
 

 
Prostate Cancer Patient Discussion Group

 

 
 
 

Coping with Prostate Cancer      Are You at Risk for Prostate Cancer?      Prostate Cancer News     Glossary

 Home     Contact Us     Disclaimer    Privacy Policy     Resources     Add URL      Site Map